Comparative evaluation of APRI, FIB-4, HFS, and NFS: Scoring tools for liver fibrosis in a Mexican population with MASLD.

Autor:	Priego-Parra BA; Centro de Investigaciones Biomédicas, Universidad Veracruzana, Veracruz, Mexico; Instituto de Investigaciones Médico-Biológicas, Universidad Veracruzana, Veracruz, Mexico., Triana-Romero A; Unidad Médica de Alta Especialidad (UMAE), Hospital de Especialidades «Dr. Bernardo Sepúlveda Gutiérrez», Centro Médico Nacional Siglo XXl, Mexico City, CDMX, Mexico., Bernal-Reyes R; Grupo de Investigación MAFLD, Asociación Mexicana de Gastroenterología, Mexico City, CDMX, Mexico., Icaza-Chávez ME; Grupo de Investigación MAFLD, Asociación Mexicana de Gastroenterología, Mexico City, CDMX, Mexico., Martínez-Vázquez SE; Grupo de Investigación MAFLD, Asociación Mexicana de Gastroenterología, Mexico City, CDMX, Mexico., Amieva-Balmori M; Instituto de Investigaciones Médico-Biológicas, Universidad Veracruzana, Veracruz, Mexico., Cano-Contreras AD; Instituto de Investigaciones Médico-Biológicas, Universidad Veracruzana, Veracruz, Mexico., Vivanco-Cid H; Instituto de Investigaciones Médico-Biológicas, Universidad Veracruzana, Veracruz, Mexico. Electronic address: HVIVANCO@uv.mx., Remes-Troche JM; Instituto de Investigaciones Médico-Biológicas, Universidad Veracruzana, Veracruz, Mexico.
Jazyk:	angličtina
Zdroj:	Revista de gastroenterologia de Mexico (English) [Rev Gastroenterol Mex (Engl Ed)] 2024 Oct-Dec; Vol. 89 (4), pp. 498-505. Date of Electronic Publication: 2024 Oct 02.
DOI:	10.1016/j.rgmxen.2024.09.002
Abstrakt:	Introduction and Aim: Liver fibrosis is a complication of metabolic dysfunction-associated steatotic liver disease (MASLD). Given the limitations and risks of liver biopsy, examining noninvasive scoring systems that are affordable for the population is necessary. Our aim was to evaluate and compare the diagnostic yield of the APRI, FIB-4, NAFLD score, and Hepamet fibrosis score instruments for detecting liver fibrosis in Mexican subjects with MASLD. Material and Methods: A retrospective study was conducted on a sample of subjects with MASLD. Liver fibrosis was calculated through transient liver elastography. Sociodemographic, epidemiologic, and biochemical variables were evaluated. Scores were calculated utilizing the fibrosis-4 (FIB-4) index, the aspartate aminotransaminase-to-platelet ratio index (APRI), the Hepamet fibrosis score (HFS), and the NAFLD score (NFS), and then compared. ROC curves were constructed, and the optimum cutoff points were determined utilizing the Youden index. Sensitivity, specificity, positive predictive value, negative predictive value, and likelihood ratio were calculated. Results: The study included 194 subjects (63% women), of whom 150 (77.3%) were classified with MASLD and 44 (22.7%) as controls with no liver disease. There was a 15.3% prevalence of advanced fibrosis. The cutoff points of 0.57 for APRI, 1.85 for FIB-4, 0.08 for HFS, and -0.058 for NFS showed diagnostic yields with areas under the ROC curves of 0.79, 0.80, 0.70, and 0.68, respectively. Conclusion: The APRI, FIB-4, NFS, and HFS scores are useful for evaluating liver fibrosis in Mexican subjects with MASLD. Better diagnostic yield was found with the FIB-4 and APRI scores. (Copyright © 2024 Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu